IP Library Granted Patent US 10,385,406
Granted Patent B2
US 10,385,406 · App. 15/471,337 · Granted Aug 20, 2019

Detection of lung neoplasia by analysis of methylated DNA

Inventors: Hatim Allawi (Middleton, WI); Graham P. Lidgard (Middleton, WI); Maria Giakoumopoulos (Middleton, WI); David A. Ahlquist (Rochester, MN); William R. Taylor (Lake City, MN); Douglas Mahoney (Rochester, MN)
Assignees: EXACT SCIENCES DEVELOPMENT COMPANY, LLC; Mayo Foundation for Medical Education and Research
C12Q1/6886C12Q1/6806C12Q2600/154C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,406
App. No.
15/471,337
Granted
Aug 20, 2019
Kind
B2
Abstract

Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.

Claims (91)

1. A method of processing a sample, the method comprising:

a) assaying a sample from a subject for an amount of at least one methylation marker selected from the group consisting of BARX1, LOC100129726, SPOCK2, TSC22D4, MAX.chr8.124, RASSF1, ZNF671, ST8SIA1, NKX6_2, FAM59B, DIDO1, MAX_Chr1.110, AGRN, SOBP, MAX_chr10.226, ZMIZ1, MAX_chr8.145, MAX_chr10.225, PRDM14, ANGPT1, MAX.chr16.50, PTGDR_9, ANKRD13B, DOCK2, MAX_chr19.163, ZNF132, MAX chr19.372, HOXA9, TRH, SP9, DMRTA2, ARHGEF4, CYP26C1, ZNF781, PTGDR, GRIN2D, MATK, BCAT1, PRKCB_28, ST8SIA_22, FLJ45983, DLX4, SHOX2, EMX1, HOXB2, MAX.chr12.526, BCL2L11, OPLAH, PARP15, KLHDC7B, SLC12A8, BHLHE23, CAPN2, FGF14, FLJ34208, B3GALT6, BIN2_Z, DNMT3A, FERMT3, NFIX, S1PR4, SKI, SUCLG2, TBX15, and ZNF329;

b) assaying said sample for an amount of a reference marker;

c) comparing the amount of said at least one methylation marker to the amount of reference marker in said sample to determine a methylation state for said at least one methylation marker in said sample; and optionally

d) generating a record reporting the methylation state for said at least one methylation marker in said sample;

wherein said sample is a plasma sample obtained from a subject having or suspected of having a lung neoplasm, and wherein said method comprises:

A) combining the plasma sample with:

i) protease; and

ii) a first lysis reagent, said first lysis reagent comprising

guanidine thiocyanate; and

non-ionic detergent;

to form a mixture wherein proteins are digested by said protease;

B) to the mixture of step a) adding

iii) silica particles, and

iv) a second lysis reagent, said second lysis reagent comprising:

guanidine thiocyanate;

non-ionic detergent; and

isopropyl alcohol;

under conditions wherein DNA is bound to said silica particles;

C) separating silica particles with bound DNA from the mixture of B);

D) to the separated silica particles with bound DNA adding a first wash solution, said first wash solution comprising a) guanidine hydrochloride or guanidine thiocyanate, and b) ethyl alcohol;

E) separating the silica particles with bound DNA from said first wash solution;

F) to the separated silica particles with bound DNA adding a second wash solution, said second wash solution comprising a buffer and ethyl alcohol;

G) separating washed silica particles with bound DNA from said second wash solution; and

H) eluting DNA from the washed silica particles with bound DNA separated in step G);

I) assaying eluted DNA for an amount of at least one methylated methylation marker and for an amount of reference marker in said eluted DNA; and

J) comparing the amount of said at least one methylated methylation marker to the amount of reference marker in said DNA to determine a methylation state for said at least one methylation marker in said plasma sample;

wherein assaying said eluted DNA comprises analyzing multiple DNA methylation markers using a PCR pre-amplification and a PCR-flap assay by a process comprising:

K) combining eluted DNA comprising a plurality of different DNA methylation marker target regions in a first reaction mixture with PCR amplification reagents, wherein said PCR amplification reagents comprise:

i) a plurality of different primer pairs for amplifying said plurality of different target regions, if present in said sample, from said eluted DNA;

ii) thermostable DNA polymerase;

iii) dNTPs; and

iv) a buffer comprising Mg ++

L) exposing said first reaction mixture to thermal cycling conditions wherein a plurality of different DNA methylation marker target regions, if present in the sample, are amplified to produce a pre-amplified mixture, and wherein said thermal cycling conditions are limited to a number of thermal cycles that maintain amplification in an exponential range;

M) partitioning said pre-amplified mixture into a plurality of PCR-flap assay reaction mixtures, wherein each PCR-flap assay reaction mixture comprises:

i) an additional amount of a primer pair selected from said plurality of different primer pairs of step K) i);

ii) thermostable DNA polymerase;

iii) dNTPs;

iv) said buffer comprising Mg ++

v) a flap endonuclease;

vi) a flap oligonucleotide; and

vi) a hairpin oligonucleotide comprising a region that is complementary to a portion of said flap oligonucleotide;

and

N) detecting amplification of one or more different DNA methylation marker target regions from said eluted DNA during PCR-flap assay reactions.

2. The method of claim 1 , wherein said assaying comprises treating the eluted DNA with a methylation-sensitive restriction enzyme or with a reagent that selectively modifies unmethylated cytosine residues in the eluted DNA.

3. The method of claim 1 , wherein said at least one methylation marker comprises a methylation marker selected from the group consisting of SLC12A8, KLHDC7B, PARP15, OPLAH, BCL2L11, MAX.chr12.526, HOXB2, EMX1, CYP26C1, SOBP, SUCLG2, SHOX2, NFIX, FLJ45983, HOXA9, B3GALT6, ZNF781, SP9, BARX1, and SKI.

4. The method of claim 1 , wherein said at least one methylation marker comprises a group of methylation markers selected from:

the group consisting of ZNF781, BARX1, and EMX1;

the group consisting of SHOX2, SOBP, ZNF781, CYP26C1, SUCLG2, and SKI;

the group consisting of SLC12A8, KLHDC7B, PARP15, OPLAH, BCL2L11, MAX.chr12.526, HOXB2, and EMX1;

the group consisting of SHOX2, SOBP, ZNF781, BTACT, CYP26C1, and DLX4;

the group consisting of SHOX2, SOBP, ZNF781, CYP26C1, SUCLG2, and SKI; and

the group consisting of ZNF781, BARX1, and EMX1, and further comprising SOBP and/or HOXA9.

5. The method of claim 1 , wherein assaying the methylation state of a methylation marker in the sample comprises determining the extent of methylation at a plurality of bases.

6. The method of claim 2 , wherein the reagent that selectively modifies unmethylated cytosine residues comprises bisulfite, and wherein said assaying comprises bisulfate converting methylation marker DNA and reference marker DNA.

7. The method of claim 1 , wherein said eluted DNA is prepared from a plasma sample of at least one mL, and wherein the volume of said eluted DNA comprising a plurality of different DNA methylation marker target regions in the first reaction mixture is at least 20 to 50% of the total volume of the first reaction mixture.

8. A method of processing a sample, the method comprising:

a) assaying a sample from a subject for an amount of at least one methylation marker selected from the group consisting of BARX1, LOC100129726, SPOCK2, TSC22D4, MAX.chr8.124, RASSF1, ZNF671, ST8SIA1, NKX62, FAM59B, DIDO1, MAX_Chr1.110, AGRN, SOBP, MAX_chr10.226, ZMIZ1, MAX_chr8.145, MAX_chr10.225, PRDM14, ANGPT1, MAX.chr16.50, PTGDR_9, ANKRD13B, DOCK2, MAX_chr19.163, ZNF132, MAX chr19.372, HOXA9, TRH, SP9, DMRTA2, ARHGEF4, CYP26C1, ZNF781, PTGDR, GRIN2D, MATK, BCAT1, PRKCB_28, ST8SIA_22, FLJ45983, DLX4, SHOX2, EMX1, HOXB2, MAX.chr12.526, BCL2L11, OPLAH, PARP15, KLHDC7B, SLC12A8, BHLHE23, CAPN2, FGF14, FLJ34208, B3GALT6, BIN2_Z, DNMT3A, FERMT3, NFIX, S1PR4, SKI, SUCLG2, TBX15, and ZNF329;

b) assaying said sample for an amount of a reference marker;

c) comparing the amount of said at least one methylation marker to the amount of reference marker in said sample to determine a methylation state for said at least one methylation marker in said sample;

wherein assaying said sample comprises analyzing multiple DNA methylation markers using a PCR pre-amplification and a PCR-flap assay by a process comprising:

I) combining DNA from the sample comprising a plurality of different DNA methylation marker target regions in a first reaction mixture with PCR amplification reagents, wherein said PCR amplification reagents comprise:

i) a plurality of different primer pairs for amplifying said plurality of different target regions, if present in the sample;

ii) thermostable DNA polymerase;

iii) dNTPs; and

iv) a buffer comprising Mg ++ ;

II) exposing said first reaction mixture to thermal cycling conditions wherein a plurality of different DNA methylation marker target regions, if present in the sample, are amplified to produce a pre-amplified mixture, and wherein said thermal cycling conditions are limited to a number of thermal cycles that maintain amplification in an exponential range;

III) partitioning said pre-amplified mixture into a plurality of PCR-flap assay reaction mixtures, wherein each PCR-flap assay reaction mixture comprises:

i) an additional amount of a primer pair selected from said plurality of different primer pairs of step I) i);

ii) thermostable DNA polymerase;

iii) dNTPs;

iv) said buffer comprising Mg ++ ;

v) a flap endonuclease;

vi) a flap oligonucleotide; and

vi) a hairpin oligonucleotide comprising a region that is complementary to a portion of said flap oligonucleotide;

and

IV) detecting amplification of one or more different DNA methylation marker target regions from said DNA from said sample during PCR-flap assay reactions.

9. The method of claim 1 , wherein said assaying comprises treating the DNA obtained from the sample with a methylation-sensitive restriction enzyme or with a reagent that selectively modifies unmethylated cytosine residues in the obtained DNA.

10. The method of claim 9 , wherein the reagent that selectively modifies unmethylated cytosine residues comprises bisulfate.

11. The method of claim 10 , wherein the assaying comprises bisulfite-converting methylation marker DNA and reference marker DNA.

12. The method of claim 8 , wherein said at least one methylation marker comprises a methylation marker selected from the group consisting of SLC12A8, KLHDC7B, PARP15, OPLAH, BCL2L11, MAX.chr12.526, HOXB2, EMX1, CYP26C1, SOBP, SUCLG2, SHOX2, NFIX, FLJ45983, HOXA9, B3GALT6, ZNF781, SP9, BARX1, and SKI.

13. The method of claim 8 , wherein said at least one methylation marker comprises a group of methylation markers selected from:

the group consisting of ZNF781, BARX1, and EMX1;

the group consisting of SHOX2, SOBP, ZNF781, CYP26C1, SUCLG2, and SKI;

the group consisting of SLC12A8, KLHDC7B, PARP15, OPLAH, BCL2L11, MAX.chr12.526, HOXB2, and EMX1;

the group consisting of SHOX2, SOBP, ZNF781, BTACT, CYP26C1, and DLX4;

the group consisting of SHOX2, SOBP, ZNF781, CYP26C1, SUCLG2, and SKI;

and

the group consisting of ZNF781, BARX1, and EMX1, and further comprising SOBP and/or HOXA9.

14. The method of claim 8 , wherein assaying the methylation state of a methylation marker in the sample comprises determining the extent of methylation at a plurality of bases.

15. The method of claim 8 , wherein said DNA from the sample is prepared from a plasma sample of at least one mL, and wherein the volume of said DNA from the sample comprising a plurality of different DNA methylation marker target regions in the first reaction mixture is at least 20 to 50% of the total volume of the first reaction mixture.

Assignments (7)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0249) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: EXACT SCIENCES CORPORATION
Reel/Frame 075288/0393 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: EXACT SCIENCES CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0249 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER ON THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 41777 FRAME: 207. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 10, 2025
From: ALLAWI, HATIM; LIDGARD, GRAHAM P.; GIAKOUMOPOULOS, MARIA
To: EXACT SCIENCES CORPORATION
Reel/Frame 069868/0676 →
MERGER Recorded Jan 14, 2022
From: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 058738/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: EXACT SCIENCES CORPORATION
To: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
Reel/Frame 044119/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2017
From: AHLQUIST, DAVID A.; MAHONEY, DOUGLAS; TAYLOR, WILLIAM R.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 041777/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2017
From: ALLAWI, HATIM; LIDGARD, GRAHAM P.; GIAKOUMOPOULOS, MARIA
To: EXACT SCIENCES CORPORATION
Reel/Frame 041777/0207 →
Continuity (3)
Provisional Application 62462677 · Feb 23, 2017
Provisional Application 62332295 · May 5, 2016
Related Publication 20170335401A1 · Nov 23, 2017
Cited By (8)
US 12,188,093 US 12,297,510 US 12,319,969 US 12,391,978 US 12,571,025 US 12,601,011 US 12,606,873 US 12,612,664